ALK and non-small cell lung carcinoma: In this study, we screened an anticancer compound library with ALK+ NSCLC cells derived from an ALK‐TKI treatment‐naïve patient and identified glutathione peroxidase 4 (GPX4) as a potential candidate that could be targeted to suppress alectinib‐induced DTP cells.